Skip to content

Study · Animal study (in vivo) · 2024

7 results

Liraglutide, a glucagon-like peptide-1 receptor agonist, inhibits bone loss in an animal model of osteoporosis with or without diabetes.

Wu Z, Deng W, Ye Y, Xu J, Han D, Zheng Y, Zheng Q

Frontiers in endocrinology29 May 2024Cited by 16 (Europe PMC)

PMID38868747 (opens in a new tab)PMCIDPMC11167098 (opens in a new tab)DOI10.3389/fendo.2024.1378291 (opens in a new tab)PepBankPUB-38868747
Download PDFPubMedAsk about this study
Jump to 7 results

Summary

IntroductionLiraglutide (Lrg), a novel anti-diabetic drug that mimics the endogenous glucagon-like peptide-1 to potentiate insulin secretion, is observed to be capable of partially reversing osteopenia. The aim of the present study is to further investigate the efficacy and potential anti-osteoporosis mechanisms of Lrg for improving bone pathology, bone- related parameters under imageology, and serum bone metabolism indexes in an animal model of osteoporosis with or without diabetes.MethodsEight databases were searched from their inception dates to April 27, 2024. The risk of bias and data on outcome measures were analyzed by the CAMARADES 10-item checklist and Rev-Man 5.3 software separately.ResultsSeventeen eligible studies were ultimately included in this review. The number of criteria met in each study varied from 4/10 to 8/10 with an average of 5.47. The aspects of blinded induction of the model, blinding assessment of outcome and sample size calculation need to be strengthened with emphasis. The pre-clinical evidence reveals that Lrg is capable of partially improving bone related parameters under imageology, bone pathology, and bone maximum load, increasing serum osteocalcin, N-terminal propeptide of type I procollagen, and reducing serum c-terminal cross-linked telopeptide of type I collagen (P<0.05). Lrg reverses osteopenia likely by activating osteoblast proliferation through promoting the Wnt signal pathway, p-AMPK/PGC1α signal pathway, and inhibiting the activation of osteoclasts by inhibiting the OPG/RANKL/RANK signal pathway through anti-inflammatory, antioxidant and anti-autophagic pathways. Furthermore, the present study recommends that more reasonable usage methods of streptozotocin, including dosage and injection methods, as well as other types of osteoporosis models, be attempted in future studies.DiscussionBased on the results, this finding may help to improve the priority of Lrg in the treatment of diabetes patients with osteoporosis.
CC BYText from Europe PMC. Highlighted sentences are the source of results.

Results from this study7

7 results from studies that gave the peptide. No result from this study comes from people.

  1. 01AnimalAnimal study (in vivo)Efficacy outcome

    In animal models of osteoporosis with or without diabetes, liraglutide partially improved bone-related parameters under imaging.

    In plain wordsIn animal models of bone loss, liraglutide partly improved bone measures seen on imaging.

    Peptide
    Liraglutide
    Outcome
    Direction not reportedBone-related parameters under imaging
    Study

    n: not reported in source

    Animal model of osteoporosis with or without diabetes
    Outcome group
    Bone and joint · Musculoskeletal
    Studied dose
    Dose not stated

    Source sentences

    Summary
    The pre-clinical evidence reveals that Lrg is capable of partially improving bone related parameters under imageology, bone pathology, and bone maximum load, increasing serum osteocalcin, N-terminal propeptide of type I procollagen, and reducing serum c-terminal cross-linked telopeptide of type I collagen (P<0.05).
    1 context sentence
    Summary · context
    Seventeen eligible studies were ultimately included in this review.
  2. 02AnimalAnimal study (in vivo)Efficacy outcome

    In animal models of osteoporosis with or without diabetes, liraglutide partially improved bone pathology.

    In plain wordsIn animal models of bone loss, liraglutide partly improved the appearance of bone tissue.

    Peptide
    Liraglutide
    Outcome
    Direction not reportedBone pathology
    Study

    n: not reported in source

    Animal model of osteoporosis with or without diabetes
    Outcome group
    Bone and joint · Musculoskeletal
    Studied dose
    Dose not stated

    Source sentences

    Summary
    The pre-clinical evidence reveals that Lrg is capable of partially improving bone related parameters under imageology, bone pathology, and bone maximum load, increasing serum osteocalcin, N-terminal propeptide of type I procollagen, and reducing serum c-terminal cross-linked telopeptide of type I collagen (P<0.05).
    1 context sentence
    Summary · context
    Seventeen eligible studies were ultimately included in this review.
  3. 03AnimalAnimal study (in vivo)Efficacy outcome

    In animal models of osteoporosis with or without diabetes, liraglutide partially improved bone maximum load.

    In plain wordsIn animal models of bone loss, liraglutide partly improved how much load bone could bear.

    Peptide
    Liraglutide
    Outcome
    IncreaseBone maximum load
    Study

    n: not reported in source

    Animal model of osteoporosis with or without diabetes
    Outcome group
    Bone and joint · Musculoskeletal
    Studied dose
    Dose not stated

    Source sentences

    Summary
    The pre-clinical evidence reveals that Lrg is capable of partially improving bone related parameters under imageology, bone pathology, and bone maximum load, increasing serum osteocalcin, N-terminal propeptide of type I procollagen, and reducing serum c-terminal cross-linked telopeptide of type I collagen (P<0.05).
    1 context sentence
    Summary · context
    Seventeen eligible studies were ultimately included in this review.
  4. 04AnimalAnimal study (in vivo)Efficacy outcome

    In animal models of osteoporosis with or without diabetes, liraglutide increased serum osteocalcin (P<0.05).

    In plain wordsIn animal models of bone loss, liraglutide raised a blood marker of bone formation, osteocalcin.

    Peptide
    Liraglutide
    Outcome
    IncreaseSerum osteocalcin
    Study

    n: not reported in source

    Animal model of osteoporosis with or without diabetes
    Outcome group
    Bone and joint · Musculoskeletal
    Studied dose
    Dose not stated

    Source sentences

    Summary
    The pre-clinical evidence reveals that Lrg is capable of partially improving bone related parameters under imageology, bone pathology, and bone maximum load, increasing serum osteocalcin, N-terminal propeptide of type I procollagen, and reducing serum c-terminal cross-linked telopeptide of type I collagen (P<0.05).
    1 context sentence
    Summary · context
    Seventeen eligible studies were ultimately included in this review.
  5. 05AnimalAnimal study (in vivo)Efficacy outcome

    In animal models of osteoporosis with or without diabetes, liraglutide increased serum N-terminal propeptide of type I procollagen (P<0.05).

    In plain wordsIn animal models of bone loss, liraglutide raised a blood marker of bone formation, procollagen propeptide.

    Peptide
    Liraglutide
    Outcome
    IncreaseSerum N-terminal propeptide of type I procollagen
    Study

    n: not reported in source

    Animal model of osteoporosis with or without diabetes
    Outcome group
    Bone and joint · Musculoskeletal
    Studied dose
    Dose not stated

    Source sentences

    Summary
    The pre-clinical evidence reveals that Lrg is capable of partially improving bone related parameters under imageology, bone pathology, and bone maximum load, increasing serum osteocalcin, N-terminal propeptide of type I procollagen, and reducing serum c-terminal cross-linked telopeptide of type I collagen (P<0.05).
    1 context sentence
    Summary · context
    Seventeen eligible studies were ultimately included in this review.
  6. 06AnimalAnimal study (in vivo)Efficacy outcome

    In animal models of osteoporosis with or without diabetes, liraglutide reduced serum c-terminal cross-linked telopeptide of type I collagen (P<0.05).

    In plain wordsIn animal models of bone loss, liraglutide lowered a blood marker of bone breakdown.

    Peptide
    Liraglutide
    Outcome
    DecreaseSerum c-terminal cross-linked telopeptide of type I collagen
    Study

    n: not reported in source

    Animal model of osteoporosis with or without diabetes
    Outcome group
    Bone and joint · Musculoskeletal
    Studied dose
    Dose not stated

    Source sentences

    Summary
    The pre-clinical evidence reveals that Lrg is capable of partially improving bone related parameters under imageology, bone pathology, and bone maximum load, increasing serum osteocalcin, N-terminal propeptide of type I procollagen, and reducing serum c-terminal cross-linked telopeptide of type I collagen (P<0.05).
    1 context sentence
    Summary · context
    Seventeen eligible studies were ultimately included in this review.
  7. 07AnimalAnimal study (in vivo)Mechanism

    In animal models of osteoporosis, liraglutide likely reversed osteopenia by promoting Wnt and p-AMPK/PGC1α signalling in osteoblasts and by inhibiting OPG/RANKL/RANK signalling in osteoclasts.

    In plain wordsIn animal models of bone loss, the review suggests liraglutide may act through bone-cell signalling pathways.

    Peptide
    Liraglutide
    Outcome
    Not applicableProposed signalling pathways of bone effect
    Study

    n: not reported in source

    Animal model of osteoporosis with or without diabetes
    Outcome group
    Receptor activity and mechanism · Musculoskeletal
    Studied dose
    Dose not stated

    Source sentences

    Summary
    Lrg reverses osteopenia likely by activating osteoblast proliferation through promoting the Wnt signal pathway, p-AMPK/PGC1α signal pathway, and inhibiting the activation of osteoclasts by inhibiting the OPG/RANKL/RANK signal pathway through anti-inflammatory, antioxidant and anti-autophagic pathways.
    1 context sentence
    Summary · context
    Seventeen eligible studies were ultimately included in this review.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    12 Oct 2026, 11:11 UTC

    Study results updated

  2. Version 1

    9 Oct 2026, 03:04 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.